BioCentury
ARTICLE | Financial News

Merganser raises $28M in series A

February 20, 2015 2:18 AM UTC

Hematology play Merganser Biotech Inc. (Newtown Square, Pa.) raised $28 million in a series A round led by new investor Novartis Venture Fund. New investors Frazier Healthcare; Sutter Hill Ventures; Osage University Partners; and existing investors BioAdvance and Stateside Developments also participated.

Merganser is developing hepcidin mimetic peptides, which are in preclinical testing to treat hematological and iron overload disorders including beta thalassemia. The company has exclusive rights to the molecules from the University of California Los Angeles and expects the lead program to enter the clinic in early 2016. ...